ATE327767T1 - Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension - Google Patents

Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension

Info

Publication number
ATE327767T1
ATE327767T1 AT01903010T AT01903010T ATE327767T1 AT E327767 T1 ATE327767 T1 AT E327767T1 AT 01903010 T AT01903010 T AT 01903010T AT 01903010 T AT01903010 T AT 01903010T AT E327767 T1 ATE327767 T1 AT E327767T1
Authority
AT
Austria
Prior art keywords
emap
pulmonary hypertension
subject
treatment
receptor antagonist
Prior art date
Application number
AT01903010T
Other languages
English (en)
Inventor
Margaret Schwarz
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of ATE327767T1 publication Critical patent/ATE327767T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01903010T 2000-01-19 2001-01-10 Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension ATE327767T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17700800P 2000-01-19 2000-01-19
US19749200P 2000-04-17 2000-04-17

Publications (1)

Publication Number Publication Date
ATE327767T1 true ATE327767T1 (de) 2006-06-15

Family

ID=26872838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01903010T ATE327767T1 (de) 2000-01-19 2001-01-10 Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension

Country Status (7)

Country Link
US (2) US20010031738A1 (de)
EP (1) EP1248641B1 (de)
AT (1) ATE327767T1 (de)
AU (1) AU3088501A (de)
CA (1) CA2397733A1 (de)
DE (1) DE60120111T2 (de)
WO (1) WO2001052879A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050160023A1 (en) * 2003-07-29 2005-07-21 Mark Pearson Systems and methods for consumers to purchase products
EP1799243B1 (de) * 2004-10-06 2015-07-15 University Of Rochester Behandlung pulmonalen hochdrucks mit einem wirkstoff, der als gewebefaktorinhibitor fungiert
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2009117680A2 (en) * 2008-03-20 2009-09-24 Indiana University Research And Technology Corporation Method for diagnosing and treating emphysema
WO2011130605A2 (en) * 2010-04-16 2011-10-20 Georgetown University Compositions and methods for treating pulmonary hypertension
CN103687621A (zh) * 2011-06-08 2014-03-26 印第安纳大学研究与技术公司 用于诊断和治疗肺疾病和损伤的单克隆抗体和抗原
US20190175502A1 (en) * 2015-10-20 2019-06-13 Indiana University Research & Technology Corporation Methods and compositions for treating lung disease of prematurity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641867A (en) * 1993-09-29 1997-06-24 The Trustees Of Columbia University In The City Of New York Antibody which specifically binds to endothelial-monocyte activating polypeptide II
US6306612B1 (en) * 1998-11-13 2001-10-23 Children Hospital Los Angeles Methods of facilitating vascular growth
US7537757B2 (en) * 1999-12-23 2009-05-26 Childrens Hospital Los Angeles Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II

Also Published As

Publication number Publication date
US20030039652A1 (en) 2003-02-27
AU3088501A (en) 2001-07-31
DE60120111D1 (de) 2006-07-06
DE60120111T2 (de) 2006-12-07
EP1248641B1 (de) 2006-05-31
US7264803B2 (en) 2007-09-04
US20010031738A1 (en) 2001-10-18
WO2001052879A1 (en) 2001-07-26
CA2397733A1 (en) 2001-07-26
EP1248641A1 (de) 2002-10-16
EP1248641A4 (de) 2003-03-26

Similar Documents

Publication Publication Date Title
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
ATE516819T1 (de) Verfahren zur behandlung von b-zell-bedingtem krebs
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ATE548025T1 (de) Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
WO2005000244A3 (en) Methods and compositions for treating rheumatoid arthritis
NO20000521D0 (no) 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE457177T1 (de) Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
ATE348812T1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
ATE327767T1 (de) Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension
DE69935331D1 (de) Verfahren und verbindungen zur behandlung der depression
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE232094T1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
DE60329326D1 (de) Tace inhibitoren
DE69820066D1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
EA200301126A1 (ru) Противоопухолевая композиция, содержащая толуолсульфонамид, и способ ее применения
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties